康华生物(300841) - 2022 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2022 reached ¥394,777,765.04, an increase of 73.29% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 49.38% to ¥167,636,572.15 in Q3 2022[5] - The net profit after deducting non-recurring gains and losses increased by 63.56% to ¥163,451,515.51 in Q3 2022[5] - The company reported a net profit margin improvement, with net profit increasing significantly due to higher revenues and controlled costs[36] - The company's net profit for the current period is 483,313,059.38 CNY, a decrease of 17.2% compared to 583,360,526.57 CNY in the previous period[40] - Operating profit for the current period is 550,937,598.24 CNY, down from 650,909,677.13 CNY, reflecting a decline of approximately 15.4%[40] - The company's basic earnings per share for Q3 2022 was ¥1.2510, down 49.16% year-on-year[5] - The basic earnings per share for the current period is 3.6067 CNY, down from 4.3343 CNY in the previous period, reflecting a decrease of approximately 16.7%[40] Assets and Liabilities - Total assets as of the end of Q3 2022 amounted to ¥3,369,347,512.87, reflecting an increase of 11.64% from the end of the previous year[5] - The total assets as of September 30, 2022, were ¥3,369,347,512.87, compared to ¥3,018,041,385.96 at the beginning of the year, indicating growth in asset base[31] - Total liabilities reached ¥405,129,612.03, compared to ¥347,740,657.31 in the previous year, indicating an increase in financial obligations[35] - The equity attributable to shareholders was ¥2,964,217,900.84, up from ¥2,670,300,728.65, reflecting a strong retained earnings position[35] - Total equity attributable to shareholders increased by 11.01% to ¥2,964,217,900.84 compared to the end of the previous year[5] Cash Flow - The company’s cash flow from operating activities showed a net increase of 62.06% year-to-date, totaling ¥19,626,743.71[5] - Cash flow from operating activities generated a net amount of 19,626,743.71 CNY, an increase from 12,111,036.04 CNY in the previous period[43] - Total cash inflow from operating activities rose by 29.89% to ¥725,750,505.53 from ¥558,736,126.98 year-on-year, attributed to higher sales collections[15] - Total cash inflow from operating activities is 725,750,505.53 CNY, compared to 558,736,126.98 CNY in the previous period, indicating a growth of 29.9%[43] - Total cash outflow from operating activities increased by 29.18% to ¥706,123,761.82 from ¥546,625,090.94, mainly due to increased R&D expenses and tax payments[15] - Cash outflow for operating activities totaled 706,123,761.82 CNY, up from 546,625,090.94 CNY, representing an increase of 29.1%[43] - The net cash flow from investing activities was -¥300,268,331.23, a decrease of 17.69% compared to -¥255,135,892.16 in the previous year[15] - The company reported a net cash outflow from investing activities of -300,268,331.23 CNY, compared to -255,135,892.16 CNY in the previous period[43] - The net cash flow from financing activities improved by 29.88% to -¥63,744,091.42 from -¥90,913,192.50[15] - Cash flow from financing activities resulted in a net outflow of -63,744,091.42 CNY, compared to -90,913,192.50 CNY in the previous period[46] Research and Development - Research and development expenses increased by 179.06% to ¥127,730,120.19 year-to-date[14] - Research and development expenses were ¥127,730,120.19, significantly higher than ¥45,771,510.81 in the previous year, reflecting a focus on innovation[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,802, with the top ten shareholders holding a combined 56.78% of shares[20] - The largest shareholder, Aokang Group Co., Ltd., held 16.12% of shares, while the second-largest shareholder, Wang Zhentao, held 13.82%[20] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[36]